<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612701</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00041957</org_study_id>
    <nct_id>NCT02612701</nct_id>
  </id_info>
  <brief_title>E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion</brief_title>
  <official_title>E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      E-cigarettes deliver nicotine by creating an aerosol of ultrafine particles. Many questions&#xD;
      remain about the size and composition and especially about the potential toxicity of these&#xD;
      particles. Thus, a key unanswered question-and the research question proposed-is whether&#xD;
      e-cigarette aerosol triggers the same acute impairment in coronary microvessel function as&#xD;
      does conventional cigarette smoke, which delivers a very well-defined exposure to fine&#xD;
      particles and many fold greater exposure to toxic (combustion) products including volatile&#xD;
      organic compounds (such as acrolein) that have been implicated in the pathogenesis of&#xD;
      tobacco-related coronary disease.&#xD;
&#xD;
      Because the effects of nicotine on the human coronary microcirculation remain incompletely&#xD;
      defined-with multiple potential vasodilator and vasoconstrictor actions each of which may&#xD;
      vary by dose-we will determine the comparative effects of conventional cigarette smoke&#xD;
      against e-cigarette aerosol with no nicotine, with low-dose nicotine, and with high-dose&#xD;
      nicotine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the pandemic we decided to terminate this project.&#xD;
  </why_stopped>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Perfusion (change in microvascular flux rate from baseline at 30 minutes)</measure>
    <time_frame>Baseline and 30 minutes after smoking</time_frame>
    <description>Myocardial contrast echocardiography will be used to measure regional myocardial perfusion - microvascular flux rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Perfusion (change in capillary blood volume from baseline at 30 minutes)</measure>
    <time_frame>Baseline and 30 minutes after smoking</time_frame>
    <description>Myocardial contrast echocardiography will be used to measure regional myocardial perfusion - capillary blood volume</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Perfusion</condition>
  <arm_group>
    <arm_group_label>Cigarettes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-cigarettes (nicotine free e-liquid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-cigarettes (low nicotine e-liquid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-cigarettes (high nicotine e-liquid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cigarettes</intervention_name>
    <description>Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)</description>
    <arm_group_label>Cigarettes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-cigarettes (nicotine free e-liquid)</intervention_name>
    <description>Subjects will smoke nicotine free e-liquid with an e-cigarette.</description>
    <arm_group_label>E-cigarettes (nicotine free e-liquid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-cigarettes (low nicotine e-liquid)</intervention_name>
    <description>Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.</description>
    <arm_group_label>E-cigarettes (low nicotine e-liquid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-cigarettes (high nicotine e-liquid)</intervention_name>
    <description>Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.</description>
    <arm_group_label>E-cigarettes (high nicotine e-liquid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-49&#xD;
&#xD;
          -  Regular cigarette smoker defined as at least 1 pack year and ≥ 5/day&#xD;
&#xD;
          -  E-cigarette smoker defined as ≥ 1/week in the last 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sub-optimal echocardiography images as determined by the sonographer and/or&#xD;
             investigators.&#xD;
&#xD;
          -  History of cardiopulmonary (including asthma or use of inhalers),&#xD;
&#xD;
          -  History of diabetes or dyslipidemia&#xD;
&#xD;
          -  History of psychiatric illness&#xD;
&#xD;
          -  Blood Pressure &gt; 140/90&#xD;
&#xD;
          -  Body Mass Index ≤ 18.5 or ≥ 30 kg•m2&#xD;
&#xD;
          -  Evidence of any of the above by physical examination, Electrocardiogram (ECG) or&#xD;
             echocardiogram&#xD;
&#xD;
          -  Resting Heart Rate &gt; 100 beats/min&#xD;
&#xD;
          -  Cardiac rhythm disorder, specifically: rhythm other than sinus, Supraventricular&#xD;
             Tachycardia (SVT), atrial fibrillation, ventricular tachycardia&#xD;
&#xD;
          -  Use of prescription medication except oral contraceptive pills&#xD;
&#xD;
          -  History of illicit drug use (self-stated)&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Any other condition(s) deemed by the physician investigators that put subjects at risk&#xD;
             for participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Rader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Florian Rader</investigator_full_name>
    <investigator_title>M.D, M.Sc.</investigator_title>
  </responsible_party>
  <keyword>Myocardial perfusion</keyword>
  <keyword>Electronic cigarettes</keyword>
  <keyword>Cigarettes</keyword>
  <keyword>Cigarette smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

